Soligenix (NASDAQ:SNGX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Soligenix (NASDAQ:SNGX) announced its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports.

Soligenix Price Performance

Soligenix stock opened at $0.29 on Friday. The company has a market capitalization of $3.02 million, a price-to-earnings ratio of -0.12 and a beta of 1.31. Soligenix has a one year low of $0.29 and a one year high of $6.23. The company’s fifty day moving average price is $1.10 and its two-hundred day moving average price is $1.28.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Soligenix currently has an average rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Soligenix

Several hedge funds have recently bought and sold shares of SNGX. Armistice Capital LLC acquired a new position in Soligenix during the third quarter worth $821,000. Two Sigma Investments LP acquired a new position in Soligenix during the third quarter worth $102,000. Virtu Financial LLC acquired a new position in Soligenix during the third quarter worth $59,000. Banco BTG Pactual S.A. acquired a new position in Soligenix during the third quarter worth $54,000. Finally, Jane Street Group LLC acquired a new position in Soligenix during the fourth quarter worth $51,000. 3.60% of the stock is owned by institutional investors and hedge funds.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.